Minerva Neurosciences (NERV) FDA Approvals $4.04 -0.41 (-9.21%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.03 -0.01 (-0.25%) As of 07/24/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Minerva Neurosciences' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Minerva Neurosciences (NERV). Over the past two years, Minerva Neurosciences has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Roluperidone. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Roluperidone (MIN-101) FDA Regulatory Events Roluperidone (MIN-101) is a drug developed by Minerva Neurosciences for the following indication: Schizophrenia. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - March 31,2026Provided Update Phase 3Drug: Roluperidone (MIN-101)Announced Date: March 31, 2026Indication: SchizophreniaAnnouncementMinerva Neurosciences, Inc. announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia. Negative symptoms, including avolition (severe lack of motivation), anhedonia (inability to experience pleasure) and social withdrawal can lead to profound personal and functional impairment and represent one of the greatest unmet needs in schizophrenia.AI SummaryMinerva Neurosciences announced that the first patient has been screened in its global, confirmatory Phase 3 trial testing roluperidone as a single (monotherapy) treatment for negative symptoms of schizophrenia. Negative symptoms—such as avolition (severe lack of motivation), anhedonia (inability to feel pleasure), and social withdrawal—can cause major personal and functional problems and are considered one of the biggest unmet needs in schizophrenia care. Roluperidone has shown consistent positive results in two prior pivotal trials, which the company says reduces development risk. It remains the only late-stage drug candidate focused specifically on this high-need patient group. The ongoing Phase 3 study aims to confirm those earlier findings, and Minerva expects to report efficacy topline data in the second half of 2027. If successful, roluperidone could offer a new option for patients whose negative symptoms are not helped by current treatments.Read AnnouncementData Presentation - March 25,2026Data Presentation Drug: Roluperidone (MIN-101)Announced Date: March 25, 2026Indication: SchizophreniaAnnouncementMinerva Neurosciences, Inc. announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25–29, 2026, at Firenze Fiera in Florence, Italy.AI SummaryMinerva Neurosciences announced that it presented clinical data from an open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25–29, 2026 in Florence, Italy. The presentation covered safety findings and trial details for clinicians and researchers attending the meeting. The trial demonstrated no safety concerns when roluperidone was given alongside olanzapine. Minerva said it is continuing to advance the program and has a confirmatory Phase 3 trial now enrolling. The company expects topline Phase 3 data in the second half of 2027, which would be an important milestone for evaluating the therapy’s effectiveness and broader safety profile. The presentation will be posted after the conference on Minerva’s website under the Presentations section at: https://tinyurl.com/MinervaPresentations.Read Announcement Minerva Neurosciences FDA Events - Frequently Asked Questions Has Minerva Neurosciences received FDA approval? As of now, Minerva Neurosciences (NERV) has not received any FDA approvals for its therapy in the last two years. What drugs has Minerva Neurosciences submitted to the FDA? In the past two years, Minerva Neurosciences (NERV) has reported FDA regulatory activity for Roluperidone (MIN-101). What is the most recent FDA event for Minerva Neurosciences? The most recent FDA-related event for Minerva Neurosciences occurred on March 31, 2026, involving Roluperidone (MIN-101). The update was categorized as "Provided Update," with the company reporting: "Minerva Neurosciences, Inc. announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia. Negative symptoms, including avolition (severe lack of motivation), anhedonia (inability to experience pleasure) and social withdrawal can lead to profound personal and functional impairment and represent one of the greatest unmet needs in schizophrenia." What conditions do Minerva Neurosciences' current drugs treat? Currently, Minerva Neurosciences has one therapy (Roluperidone (MIN-101)) targeting the following condition: Schizophrenia. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Estrella Immunopharma FDA EventsGilead Sciences FDA EventsPrima BioMed FDA EventsMannKind FDA EventsNewAmsterdam Pharma FDA EventsOrganon & Co. FDA EventsBeam Therapeutics FDA EventsGenmab A/S FDA EventsHCW Biologics FDA EventsInhibikase Therapeutics FDA EventsIncannex Healthcare FDA EventsLantern Pharma FDA EventsJohnson & Johnson FDA EventsEli Lilly and Company FDA EventsArrowhead Pharmaceuticals FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Aclaris Therapeutics FDA Events Design Therapeutics FDA Events Bright Minds Biosciences FDA Events Monopar Therapeutics FDA Events Aura Biosciences FDA Events Candel Therapeutics FDA Events Climb Bio FDA Events Forte Biosciences FDA Events Gyre Therapeutics FDA Events Allogene Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:NERV last updated on 4/1/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersThe comeback story of the century (ticker inside)In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of ...InvestorPlace | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredUniversal basic income is not impossible. It exist (kind of)Robert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredThe 90%-off options that empty accountsA call that cost $3.00 last month now trades for $0.30 - a 90% discount that looks tempting. It's not a bar...Profits Run | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - March 31,2026Provided Update Phase 3Drug: Roluperidone (MIN-101)Announced Date: March 31, 2026Indication: SchizophreniaAnnouncementMinerva Neurosciences, Inc. announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia. Negative symptoms, including avolition (severe lack of motivation), anhedonia (inability to experience pleasure) and social withdrawal can lead to profound personal and functional impairment and represent one of the greatest unmet needs in schizophrenia.AI SummaryMinerva Neurosciences announced that the first patient has been screened in its global, confirmatory Phase 3 trial testing roluperidone as a single (monotherapy) treatment for negative symptoms of schizophrenia. Negative symptoms—such as avolition (severe lack of motivation), anhedonia (inability to feel pleasure), and social withdrawal—can cause major personal and functional problems and are considered one of the biggest unmet needs in schizophrenia care. Roluperidone has shown consistent positive results in two prior pivotal trials, which the company says reduces development risk. It remains the only late-stage drug candidate focused specifically on this high-need patient group. The ongoing Phase 3 study aims to confirm those earlier findings, and Minerva expects to report efficacy topline data in the second half of 2027. If successful, roluperidone could offer a new option for patients whose negative symptoms are not helped by current treatments.Read Announcement
Data Presentation - March 25,2026Data Presentation Drug: Roluperidone (MIN-101)Announced Date: March 25, 2026Indication: SchizophreniaAnnouncementMinerva Neurosciences, Inc. announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25–29, 2026, at Firenze Fiera in Florence, Italy.AI SummaryMinerva Neurosciences announced that it presented clinical data from an open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25–29, 2026 in Florence, Italy. The presentation covered safety findings and trial details for clinicians and researchers attending the meeting. The trial demonstrated no safety concerns when roluperidone was given alongside olanzapine. Minerva said it is continuing to advance the program and has a confirmatory Phase 3 trial now enrolling. The company expects topline Phase 3 data in the second half of 2027, which would be an important milestone for evaluating the therapy’s effectiveness and broader safety profile. The presentation will be posted after the conference on Minerva’s website under the Presentations section at: https://tinyurl.com/MinervaPresentations.Read Announcement
